This observation will require further evaluation in larger cohorts because carriers of BRCA1/BRCA2 mutation develop BC significantly earlier than non-carriers and many published studies focused primarily on early-onset BC patients or had enriched this subgroup as a result of criteria for genetic testing [10,13,19]. This evidence concerns the gene BRCA2 and breast cancer.